Differential responses to chemoimmunotherapy in patients with metastatic malignant melanoma

European Journal of Cancer Part A

Volumn 33, Issue 9, 1997, Pages 1388-1392

  Mainwaring, P N ^a   Atkinson, H ^a   Chang, J ^a   Moore, J ^a   Hancock, B W ^b   Guillou, P J ^c   Oskam, R ^d   Gore, M E ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b WESTON PARK HOSPITAL   (United Kingdom)

^c ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^d Chiron BV   (Netherlands)

Author keywords

Chemoimmunotherapy; Cisplatin; Differential responses; Interferon ; Interleukin 2; Melanoma

Indexed keywords

ANTINEOPLASTIC AGENT; CARMUSTINE; CISPLATIN; DACARBAZINE; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT INTERLEUKIN 2; TAMOXIFEN; VINDESINE;

ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG INDUCED DISEASE; DRUG INFUSION; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MELANOMA; METASTASIS; MULTICENTER STUDY; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CISPLATIN; COMBINED MODALITY THERAPY; CYTOKINES; FEMALE; HUMANS; IMMUNOTHERAPY; INTERFERON TYPE I, RECOMBINANT; INTERLEUKIN-2; MALE; MELANOMA; MIDDLE AGED; RECOMBINANT PROTEINS; SURVIVAL RATE;

EID: 0030824159     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(97)00104-4     Document Type: Article

References (23)

1. Garbo C. Chemotherapy and chemoimmunotherapy in disseminated malignant melanoma. Melanoma Res 1993, 3, 291-299.
2. Coates AS, Segelov E. Long term response to chemotherapy in patients with visceral metastatic melanoma. Ann Oncol 1994, 5, 249-251.
3. Legha S. Interferons in the treatment of malignant melanoma. Cancer 1986, 57, 1675-1677.
4. Whittington R, Faulds D. Interleukin-2: a review of its pharmacological properties and therapeutic use in patients with cancer. Drugs 1993, 46, 446-514.
5. Takaku F. Clinical application of cytokines for cancer treatment. Oncology Switzerland 1994, 51, 123-128.
6. Aapro MS. Advances in systemic treatment of malignant melanoma. Eur J Cancer Part A Gen Top 1993, 29, 613-617.
7. Rosenberg SA. The immunotherapy and gene therapy of cancer. J Clin Oncol 1992, 10, 180-199.
8. West WH, Tauer KW, Yannelli JR, Marshall GD, Orr DW, Thurman GB, RKO. Constant infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med 1987, 316, 898-905.
9. Oppenheim MH, Lotze MT. Interleukin 2: solid-tumor therapy. Oncology Switzerland 1994, 51, 154-169.
10. Ghosh AK, Cerny T, Wagstaff J, Thatcher N, Moore M. Effect on in vivo administration of interferon gamma on expression of MHC products and tumour associated antigens in patients with metastatic melanoma. Eur J Cancer Clin Oncol 1989, 25, 1637-1643.
11. Neefe J, Dritschilo A. Complete response in melanoma treated with interferon is a direct antiproliferative effect. Proc Annu Am Soc Clin Oncol 1987, 6, 243.
12. Agarwala SS, Kirkwood JM. Interferons in the therapy of solid tumors. Oncology Switzerland 1994, 51, 129-136.
13. Truitt GA, Brunda MJ, Levitt D, Anderson TD, Sherman MI. The therapeutic activity in cancer of IL-2 in combination with other cytokines. Cancer Surv 1989, 8, 875-889.
14. Rosenberg SA, Lotze MT, Yang JC, et al. Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer. J Clin Oncol 1989, 7, 1863-1874.
15. Castello G, Ruocco V, Satriano RA, Zarilli D. Role of interferons in the therapy of melanoma. Melanoma Res 1991, 1, 311-325.
16. Wadler S, Schwartz EL. Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: a review. Cancer Res 1990, 50, 3473-3486.
17. Demchak PA, Mier JW, Robert NJ, O'Brien K, Gould JA, Atkins MB. Interleukin-2 and high-dose cisplatin in patients with metastatic melanoma: a pilot study. J Clin Oncol 1991, 9, 1821-1830.
18. Richner J, Cerny T, Joss RA, Misksche M, Brunner KW. A phase II study of continuous s.c. alpha-2b interferon (IFN) combined with cisplatin (CDDP) in advanced malignant melanoma (MM). Proc Annu Meet Am Soc Clin Oncol 1990, 9, 280.
19. Hamblin TJ, Davies B, Sadullah S, Oskam R, Palmer P, Franks CR. A phase II study of the treatment of metastatic malignant melanoma with a combination of dacarbazine, ciplatin, interleukin-2 (IL-2) and alfa-interferon (IFN) (meeting abstract). Proc Annu Meet Am Soc Clin Oncol 1991, 10, 294.
20. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981, 47, 207-214.
21. Khayat D, Borel C, Tourani JM, et al. Sequential chemoimmunotherapy with cisplatin, interleukin-2, and interferon alfa-2a for metastatic melanoma. J Clin Oncol 1993, 11, 2173-2180.
22. Richards J, Mehta N, Schroeder L, Dordal A. Sequential chemotherapy/immunotherapy for metastic melanoma (meeting abstract). Proc Annu Meet Am Soc Clin Oncol 1992, 11, 346.
23. Buzaid AC, Legha SS. Combination of chemotherapy with interleukin-2 and interferon-alfa for the treatment of advanced melanoma. Semin Oncol 1994, 21, 23-28.